PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

Huang, C. H., Williamson, S. K., VanVeldhuizen, P. J., Hsueh, C. T., Allen, A., Smith, H., … Kelly, K. (2008). PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. Journal of Clinical Oncology, 26(15_suppl), 19055–19055. https://doi.org/10.1200/jco.2008.26.15_suppl.19055